# Olema Pharmaceuticals, Inc.: overview OLMA · Nasdaq · CIK 1750284 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/olma.md) · [Financials](/companies/olma/financials.md) · [Filings](/companies/olma/filings.md) · [Insiders](/companies/olma/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.60)](/filings/0001193125-25-273236.md) | not reported | [(0.36)](/filings/0001193125-26-218156.md) | [(0.51)](/filings/0001193125-26-342383.md) | [(0.49)](/filings/0001193125-25-273236.md) | not reported | [(0.52)](/filings/0001193125-26-218156.md) | [(0.61)](/filings/0001193125-26-342383.md) | | Free cash flow | $m | [(27.0) d](/filings/0001193125-25-273236.md) | [(26.3) d](/filings/0001193125-26-107169.md) | not reported | not reported | [(34.5) d](/filings/0001193125-25-273236.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.80)](/filings/0001558370-23-003318.md) | [(2.62)](/filings/0000950170-24-029281.md) | [(2.14)](/filings/0000950170-25-041204.md) | [(2.20)](/filings/0001193125-26-107169.md) | [(1.87)](/filings/0001193125-26-107169.md) | | Free cash flow | $m | [(52.3)](/filings/0001558370-23-003318.md) | [(82.4)](/filings/0000950170-24-029281.md) | not reported | [(105)](/filings/0001193125-26-107169.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/olma/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $151.9m | 12,143,062 | | Added +1,756,217 | | [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $108.5m | 8,670,576 | | Added +650,000 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $106.0m | 7,108,488 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $88.8m | 7,094,413 | | Not compared | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $88.6m | 7,085,249 | | Reduced −387,989 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $84.0m | 6,714,691 | | Added +1,062,556 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $66.3m | 5,295,893 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $60.8m | 4,856,949 | | Added +100,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $54.0m | 4,316,058 | | Added +378,227 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $41.8m | 3,341,217 | | Added +257,700 | ## Recent filings [All 561 filings](/companies/olma/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 21:58 ET | [SCHEDULE 13D/A](/filings/0000921895-26-002806.md) | Ownership report, active investor, amended | 0000921895-26-002806 | | 2026-10-15 | 21:00 ET | [8-K](/filings/0001193125-26-423002.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-423002 | | 2026-08-13 | 11:05 ET | [8-K](/filings/0001193125-26-347853.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-347853 | | 2026-08-10 | 20:10 ET | [10-Q](/filings/0001193125-26-342383.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342383 | | 2026-08-10 | 20:05 ET | [8-K](/filings/0001193125-26-342334.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342334 | | 2026-06-23 | 20:19 ET | [8-K](/filings/0001193125-26-279483.md) | 5.07 Shareholder vote results | 0001193125-26-279483 | | 2026-05-26 | 11:05 ET | [8-K](/filings/0001193125-26-237832.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-237832 | | 2026-05-21 | 21:05 ET | [8-K](/filings/0001193125-26-234848.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-234848 | | 2026-05-12 | 11:10 ET | [10-Q](/filings/0001193125-26-218156.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218156 | | 2026-05-12 | 11:05 ET | [8-K](/filings/0001193125-26-218142.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-218142 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-107169.md), filed Mar 16, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1750284 - Tickers: OLMA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.